ERBB2 and neoplasm: Preferential unmasking of fluorophore-labeled HER2-XPAT and EpCAM-XPAT proteins was evident in tumors 48 h after administration to BT-474 and PDX tumor-bearing mice versus heart, brain, liver and spleen tissues.